DOCSLIB.ORG

ESID Registry – Working Definitions for Clinical Diagnosis of PID

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ESID Registry – Working Definitions for Clinical Diagnosis of PID ESID Registry – Working Definitions for Clinical Diagnosis of PID These criteria are only for patients with no genetic diagnosis*. *Exceptions: Atypical SCID, DiGeorge syndrome – a known genetic defect and confirmation of criteria is mandatory Available entries (Please click on an entry to see the criteria.) Page Agammaglobulinaemia ................................................................................................................................................................ 4 Asplenia syndrome (Ivemark syndrome) ................................................................................................................................... 4 Ataxia telangiectasia (ATM) ......................................................................................................................................................... 4 Autoimmune lymphoproliferative syndrome (ALPS) ................................................................................................................ 4 APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) .................. 5 Barth syndrome ............................................................................................................................................................................ 5 Bloom syndrome .......................................................................................................................................................................... 6 Cartilage hair hypoplasia (CHH) .................................................................................................................................................. 6 Chronic mucocutaneous candidiasis (CMC) ............................................................................................................................. 7 Complement component 2 deficiency ........................................................................................................................................ 7 Complement component 3 deficiency (C3) ................................................................................................................................ 7 CSR defects and HIGM syndromes ............................................................................................................................................. 8 Chediak Higashi syndrome (CHS) ............................................................................................................................................... 8 Chronic granulomatous disease (CGD) ...................................................................................................................................... 9 Clericuzio-type poikiloderma with neutropenia syndrome ....................................................................................................... 9 COHEN syndrome ........................................................................................................................................................................ 9 Combined immunodeficiency (CID) .......................................................................................................................................... 10 Common variable immunodeficiency disorders (CVID) .......................................................................................................... 10 Congenital neutropenia ............................................................................................................................................................. 11 Cyclic neutropenia ..................................................................................................................................................................... 11 Defects of TLR/NFkappa-B signalling ....................................................................................................................................... 11 Defects with susceptibility to mycobacterial infection (MSMD) ............................................................................................. 11 Deficiency of specific IgG (Specific antibody deficiency - SPAD) ......................................................................................... 12 DiGeorge syndrome ................................................................................................................................................................... 12 Dyskeratosis congenita ............................................................................................................................................................. 12 Factor D deficiency .................................................................................................................................................................... 12 Familial hemophagocytic lymphohistiocytosis syndromes (FHLH) ...................................................................................... 13 FOXP3 deficiency (IPEX) ............................................................................................................................................................ 13 Glycogen storage disease type 1b (GS1b) ............................................................................................................................... 13 ESID Registry - Working definitions for clinical diagnosis of PID July 18, 2016 page 1 of 25 Griscelli syndrome type 2 .......................................................................................................................................................... 14 Hereditary Angioedema (C1inh) ................................................................................................................................................ 14 Hermansky-Pudlak syndrome (type 2) ..................................................................................................................................... 14 HLA class I deficiency ................................................................................................................................................................ 15 HLA class II deficiency (MHC2) ................................................................................................................................................. 15 Hoyeraal-Hreidarsson syndrome .............................................................................................................................................. 15 Hyper IgE syndrome (HIES) ....................................................................................................................................................... 16 IgA with IgG subclass deficiency .............................................................................................................................................. 16 Immunodeficiency centromeric instability facial anomalies syndrome (ICF) ....................................................................... 16 IPEX-like disease ........................................................................................................................................................................ 17 Isolated IgG subclass deficiency .............................................................................................................................................. 17 Isolated congenital asplenia ...................................................................................................................................................... 17 Mannose-binding lectin deficiency (MBL) ................................................................................................................................ 17 Nijmegen breakage syndrome .................................................................................................................................................. 18 Omenn syndrome ....................................................................................................................................................................... 18 Partial albinism and immunodeficiency syndrome ................................................................................................................. 19 Properdin P factor complement deficiency (PFC) ................................................................................................................... 19 Schimke disease......................................................................................................................................................................... 19 Seckel syndrome ........................................................................................................................................................................ 20 Selective CD4 cell deficiency .................................................................................................................................................... 20 Selective IgA deficiency ............................................................................................................................................................. 20 Selective IgM deficiency ............................................................................................................................................................ 21 Severe combined immunodeficiency (SCID) ........................................................................................................................... 21 Shwachman-Diamond-syndrome .............................................................................................................................................
Load more

Recommended publications
  • Allergy, Asthma & Immunology Associates (Private Practice) 2808
    CURRICULUM VITAE Roger H. Kobayashi, M.D. Business Address: Allergy, Asthma & Immunology Associates (Private practice) 2808 South 80th Avenue, Suites 210 and 240, Omaha, NE 68124 (402) 391-1800 Fax (402) 391-1563 email: [email protected] Education: 6/1969 University of Nebraska, Lincoln, Nebraska, B.A. (Pre-Med/Economics) 9/69-6/73 University of Hawaii Medical School, Honolulu, Hawaii 6/72-5/75 University of Hawaii Graduate School, Honolulu, Hawaii, M.S. (Physiology) 9/74-4/75 UCSD School of Medicine & UCLA School of Medicine 7/73-5/75 University of Nebraska College of Medicine, Omaha, Nebraska, M.D. Academic Positions: 6/75-7/76 Pediatric Intern, University of Southern California School of Medicine, Los Angeles, California 7/76-7/77 Pediatric Resident, University of Southern California School of Medicine, Los Angeles, California 7/77-12/79 Fellowship, Pediatric Immunology & Allergy, UCLA School of Medicine, Los Angeles, California 1/80-6/84 Assistant Professor of Pediatrics and Medical Microbiology, University of Nebraska College of Medicine, Omaha, Nebraska 1/80-9/88 Director, Division of Allergy and Immunology, Department of Pediatrics, University of Nebraska 7/84-9/88 Associate Professor of Pediatrics, University of Nebraska College of Medicine 7/85-9/88 Associate Professor of Pathology and Medical Microbiology, University of Nebraska College of Medicine 9/88-1/90 Associate Professor of Pediatrics, UCLA School of Medicine, Los Angeles, CA 1/90-6/95 Assoc Clinical Prof of Pediatrics UCLA School of Medicine, Los Angeles, CA 6/95-present
    [Show full text]
  • The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria.Pdf
    The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria Richard John Kelly Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds School of Medicine January 2014 1 Jointly-Authored Publications The candidate confirms that the work submitted is his own, except where work which has formed part of jointly authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. The work in Chapter 3 of the thesis has appeared in publication as follows: Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-6792. I was responsible for designing the study, collecting and analysing the data and writing the paper. Dena Cohen and Walter Gregory performed the statistical analysis. All the other authors reviewed the paper. The work in Chapter 4 of the thesis has appeared in publication as follows: Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010;149:446-450. I was responsible for designing the study, collecting and analysing the data and writing the paper.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Somatic Mosaicism in Wiskott–Aldrich Syndrome Suggests in Vivo Reversion by a DNA Slippage Mechanism
    Somatic mosaicism in Wiskott–Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism Taizo Wada*, Shepherd H. Schurman*, Makoto Otsu*, Elizabeth K. Garabedian*, Hans D. Ochs†, David L. Nelson‡, and Fabio Candotti*§ *Disorders of Immunity Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; †Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195; and ‡Immunophysiology Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 Communicated by Francis S. Collins, National Institutes of Health, Bethesda, MD, May 24, 2001 (received for review April 23, 2001) Somatic mosaicism caused by in vivo reversion of inherited muta- of whom showed a progressively mild clinical course because of tions has been described in several human genetic disorders. Back the selective growth advantage of the revertant lymphocytes. mutations resulting in restoration of wild-type sequences and The molecular mechanism leading to the reversion events has second-site mutations leading to compensatory changes have been remained unknown in most cases, except for the few cases where shown in mosaic individuals. In most cases, however, the precise crossing over or gene conversion has been shown in compound genetic mechanisms underlying the reversion events have re- heterozygous patients (11, 12). DNA polymerase slippage is the mained unclear, except for the few instances where crossing over most commonly invoked mechanism to explain triplet repeat or gene conversion have been demonstrated. Here, we report a expansion in human diseases (e.g., Huntington’s disease, fragile patient affected with Wiskott–Aldrich syndrome (WAS) caused by X syndrome, and Friedreich ataxia) (16).
    [Show full text]
  • The Case for Lupus Nephritis
    Journal of Clinical Medicine Review Expanding the Role of Complement Therapies: The Case for Lupus Nephritis Nicholas L. Li * , Daniel J. Birmingham and Brad H. Rovin Department of Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH 43210, USA; [email protected] (D.J.B.); [email protected] (B.H.R.) * Correspondence: [email protected]; Tel.: +1-614-293-4997; Fax: +1-614-293-3073 Abstract: The complement system is an innate immune surveillance network that provides defense against microorganisms and clearance of immune complexes and cellular debris and bridges innate and adaptive immunity. In the context of autoimmune disease, activation and dysregulation of complement can lead to uncontrolled inflammation and organ damage, especially to the kidney. Systemic lupus erythematosus (SLE) is characterized by loss of tolerance, autoantibody production, and immune complex deposition in tissues including the kidney, with inflammatory consequences. Effective clearance of immune complexes and cellular waste by early complement components protects against the development of lupus nephritis, while uncontrolled activation of complement, especially the alternative pathway, promotes kidney damage in SLE. Therefore, complement plays a dual role in the pathogenesis of lupus nephritis. Improved understanding of the contribution of the various complement pathways to the development of kidney disease in SLE has created an opportunity to target the complement system with novel therapies to improve outcomes in lupus nephritis. In this review, we explore the interactions between complement and the kidney in SLE and their implications for the treatment of lupus nephritis. Keywords: lupus nephritis; complement; systemic lupus erythematosus; glomerulonephritis Citation: Li, N.L.; Birmingham, D.J.; Rovin, B.H.
    [Show full text]
  • Comprehensive Genetic Testing for Primary Immunodeficiency
     Woon and Ameratunga Allergy Asthma Clin Immunol (2016) 12:65 Allergy, Asthma & Clinical Immunology DOI 10.1186/s13223-016-0169-2 RESEARCH Open Access Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10‑year experience in Auckland, New Zealand See‑Tarn Woon and Rohan Ameratunga* Abstract Background and purpose: New Zealand is a developed geographically isolated country in the South Pacific with a population of 4.4 million. Genetic diagnosis is the standard of care for most patients with primary immunodeficiency disorders (PIDs). Methods: Since 2005, we have offered a comprehensive genetic testing service for PIDs and other immune-related disorders with a published sequence. Here we present results for this program, over the first decade, between 2005 and 2014. Results: We undertook testing in 228 index cases and 32 carriers during this time. The three most common test requests were for X-linked lymphoproliferative (XLP), tumour necrosis factor receptor associated periodic syndrome (TRAPS) and haemophagocytic lymphohistiocytosis (HLH). Of the 32 suspected XLP cases, positive diagnoses were established in only 2 patients. In contrast, genetic defects in 8 of 11 patients with suspected X-linked agammaglobu‑ linemia (XLA) were confirmed. Most XLA patients were initially identified from absence of B cells. Overall, positive diagnoses were made in about 23% of all tests requested. The diagnostic rate was lowest for several conditions with locus heterogeneity. Conclusions: Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic service has worked effectively for New Zealand. Next genera‑ tion sequencing will play an increasing role in disorders with locus heterogeneity.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Agammaglobulinemia Hypogammaglobulinemia Hereditary Disease Immunoglobulins
    Pediat. Res. 2: 72-84 (1968) Agammaglobulinemia hypogammaglobulinemia hereditary disease immunoglobulins Hereditary Alterations in the Immune Response: Coexistence of 'Agammaglobulinemia', Acquired Hypogammaglobulinemia and Selective Immunoglobulin Deficiency in a Sibship REBECCA H. BUCKLEY[75] and J. B. SIDBURY, Jr. Departments of Pediatrics, Microbiology and Immunology, Division of Immunology, Duke University School of Medicine, Durham, North Carolina, USA Extract A longitudinal immunologic study was conducted in a family in which an entire sibship of three males was unduly susceptible to infection. The oldest boy's history of repeated severe infections be- ginning in infancy and his marked deficiencies of all three major immunoglobulins were compatible with a clinical diagnosis of congenital 'agammaglobulinemia' (table I, fig. 1). Recurrent severe in- fections in the second boy did not begin until late childhood, and his serum abnormality involved deficiencies of only two of the major immunoglobulin fractions, IgG and IgM (table I, fig. 1). This phenotype of selective immunoglobulin deficiency is previously unreported. Serum concentrations of the three immunoglobulins in the youngest boy (who also had a late onset of repeated infection) were normal or elevated when he was first studied, but a marked decline in levels of each of these fractions was observed over a four-year period (table I, fig. 1). We could find no previous reports describing apparent congenital and acquired immunologic deficiencies in a sibship. Repeated infections and demonstrated specific immunologic unresponsiveness preceded gross ab- normalities in the total and fractional gamma globulin levels in both of the younger boys (tables II-IV). When the total immunoglobulin level in the second boy was 735 mg/100 ml, he failed to respond with a normal rise in titer after immunization with 'A' and 'B' blood group substances, diphtheria, tetanus, or Types I and II poliovaccines.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Asplenia Vaccination Guide
    Stanford Health Care Vaccination Subcommitee Revision date 11/308/2018 Functional or Anatomical Asplenia Vaccine Guide I. PURPOSE To outline appropriate vaccines targeting encapsulated bacteria for functionally or anatomically asplenic patients. Routine vaccines that may also be indicated but not addressed here include influenza, Tdap, herpes zoster, HPV, MMR, and varicella.1,2,3 II. Background Functionally or anatomically asplenic patients should be vaccinated to decrease the risk of sepsis due to organisms such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis. Guidelines are based on CDC recommendations. For additional information, see https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. III. Procedures/Guidelines1,2,3,6,7,8 The regimen consists of 4 vaccines initially, followed by repeat doses as specified: 1. Haemophilus b conjugate (Hib) vaccine (ACTHIB®) IM once if they have not previously received Hib vaccine 2. Pneumococcal conjugate 13-valent (PCV13) vaccine (PREVNAR 13®) IM once • 2nd dose: Pneumococcal polysaccharide 23-valent (PPSV23) vaccine (PNEUMOVAX 23®) SQ/IM once given ≥ 8 weeks later, then 3rd dose as PPSV23 > 5 years later.4 Note: The above is valid for those who have not received any pneumococcal vaccines previously, or those with unknown vaccination history. If already received prior doses of PPSV23: give PCV13 at least 1 year after last PPSV23 dose. 3. Meningococcal conjugate vaccine (MenACWY-CRM, MENVEO®) IM (repeat in ≥ 8 weeks, then every 5 years thereafter) 4. Meningococcal serogroup B vaccine (MenB, BEXSERO®) IM (repeat in ≥ 4 weeks) Timing of vaccination relative to splenectomy: 1. Should be given at least 14 days before splenectomy, if possible.
    [Show full text]
  • Standards of Medical Fitness
    Army Regulation 40–501 Medical Services Standards of Medical Fitness Rapid Action Revision (RAR) Issue Date: 23 August 2010 Headquarters Department of the Army Washington, DC 14 December 2007 UNCLASSIFIED SUMMARY of CHANGE AR 40–501 Standards of Medical Fitness This rapid action revision, dated 23 August 2010-- o Clarifies waiver authorities for officer accessions and commissions for the U.S. Military Academy, Reserve Officers’ Training Corps, and Officer Candidate School (paras 1-6c and 1-6e). o Updates the medical retention standards for psychiatric disorders and hearing (paras 3-10 and 3-31). o Adds a requirement for referral to a Medical Evaluation Board for rhabdomyolysis (para 3-40). o Provides new definitions for heat illness and reasons for a Medical Evaluation Board (para 3-45). o Clarifies who has ultimate responsibility to determine whether to deploy a Soldier (para 5-14d, 5-14e, and 5-14f). o Updates deployment-limiting psychiatric medical conditions (para 5-14f(8)). o Updates functional activities to reflect content changes to DA Form 3349, Physical Profile (chap 7). o Requires review of all permanent 3 and 4 profiles by a Medical Evaluation Board physician or other physician approval authority (para 7-4b). o Establishes and defines the term Medical Retention Determination Point (para 7-4b(2)). o Allows physician assistants, nurse practitioners, and nurse midwives to write permanent profiles as the profiling officer (para 7-6a(4)). o Changes administrative code designations for physical profiles (table 7-2). o Adds psychiatric evaluations for certain administrative separations (paras 8-24a(1) and 8-24a(2)).
    [Show full text]